1. Paget J. On a form of chronic inflammation of bones. (Osteitis deformans). Med Chir Trans. 1877;60:37.

2. Leopold-Levi M, Londe A. Application des rayons de Roentgen a l'etude de la texture. N. iconog. de la Salpetriere, Paris. 1897;X:198-201.

3. Beclere M. Radiographie d'un cas de maladie de Paget. Bull Mem Soc Med Hop Paris. 1901;18:929-931.

4. Kay H. Plasma phosphatase in osteitis deformans and in other diseases of bone. Brit. J. Exp. Path. 1929;10:253.

5. Barker DJ, Chamberlain AT, Guyer PB, Gardner MJ. Paget's disease of bone: the Lancashire focus. Br Med J. 1980;280:1105-1107.

6. Altman RD, Bloch DA, Hochberg MC, Murphy WA. Prevalence of pelvic Paget's disease of bone in the United States. J Bone Miner Res. 2000;15:461-465.

7. Lecuyer N, Grados F, Dargent-Molina P, Deramond H, Meunier PJ, Fardellone P. Prevalence of Paget's disease of bone and spinal hemangioma in French women older than 75 years: data from the EPIDOS study. Joint Bone Spine. 2000;67:315-318.

8. Cundy HR, Gamble G, Wattie D, Rutland M, Cundy T. Paget’s disease of bone in New Zealand: Continued decline in disease severity. Calcif Tissue Int. 2004:75;358-364.

9. Poor G, Donath J, Fornet B, Copper C. Epidemiology of Paget’s disease in Europe: the prevalence is decreasing. J Bone Miner Res. 2006;21(10):1545-9.

10. Tiegs RD, Lohse CM, Wollan PC, Melton LJ. Long-term trends in the incidence of Paget's disease of bone. Bone. 2000;27:423-427.

11. Eekhoff ME, van der Klift M, Kroon HM, Cooper C, Hofman A, Pols HA, Papapoulos SE. Paget’s disease of bone in The Netherlands: a population-based radiological and biochemical survey—the Rotterdam Study. J Bone Miner Res. 2004:19;566-570.

12. Schmorl G. Uber Osteitis deformans Paget. Virchows Arch. 1932;283:694-751.

13. Pick. Osteitis deformans. Lancet. 1883;2:1125-1126.

14. McKusick V. Heritable Disorders of Connective Tissue. St. Louis: Mosby; 1972.

15. Sofaer JA, Holloway SM, Emery AE. A family study of Paget's disease of bone. J Epidemiol Community Health. 1983;37:226-231.

16. Siris ES, Ottman R, Flaster E, Kelsey JL. Familial aggregation of Paget's disease of bone. J Bone Miner Res. 1991;6:495-500.

17. Morales-Piga AA, Rey-Rey JS, Corres-Gonzalez J, Garcia-Sagredo JM, Lopez-Abente G. Frequency and characteristics of familial aggregation of Paget's disease of bone. J Bone Miner Res. 1995;10:663-670.

18. Kanis J. Pathophysiology and treatment of Paget's disease of bone. In: Fogelman I, ed. London: Martin Dunitz Ltd; 1991.

19. Haddaway MJ, Davie MW, McCall IW, Howdle S. Effect of age and gender on the number and distribution of sites in Paget’s disease of bone. Br J Radiol. 2007;80(955):532-6.

20. Monsell EM. The mechanism of hearing loss in Paget’s disease of bone. Laryngoscope. 2004;114;598-606.

21. Smith BJ, Eveson JW. Paget's disease of bone with particular reference to dentistry. J Oral Pathol. 1981;10:233-247.

22. Dove J. Complete fractures of the femur in Paget's disease of bone. J Bone Joint Surg Br. 1980;62-B:12-17.

23. Schuller A. Dysostosis hypophysaria. Brit. J. Radiol. 1926;31:156-158.

24. Maldague B, Malghem J. Dynamic radiologic patterns of Paget's disease of bone. Clin Orthop. 1987:126-151.

25. Miller SW, Castronovo FP, Jr., Pendergrass HP, Potsaid MS. Technetium 99m labeled diphosphonate bone scanning in Paget's disease. Am J Roentgenol Radium Ther Nucl Med. 1974;121:177-183.

26. Waxman AD, McKee D, Siemsen JK, Singer FR. Gallium scanning in Paget's disease of bone: effect of calcitonin. Am J Roentgenol. 1980;134:303-306.

27. Cook GJ, Maisey MN, Fogelman I. Fluorine-18-FDG PET in Paget's disease of bone. J Nucl Med. 1997;38:1495-1497.

28. Abamor E, Kitapci MT, Cila E, Gokcora N, Uluoglu O. Increased accumulation of Tl-201 in monostotic Paget's disease of the patella: evaluation with quantitative analysis. Clin Nucl Med. 2001;26:615-618.

29. Rubinstein M, Smelin A, Freedman A. Osteoblasts and osteoclasts in bone marrow aspiration. Arch Intern Med. 1953;92:684-696.

30. Meunier PJ, Coindre JM, Edouard CM, Arlot ME. Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue. Arthritis Rheum. 1980;23:1095-1103.

31. Rebel A, Malkani K, Basle M. [Nuclear anomalies in osteoclasts in Paget's bone disease]. Nouv Presse Med. 1974;3:1299-1301.

32. Mills BG, Singer FR. Nuclear inclusions in Paget's disease of bone. Science. 1976;194:201-202.

33. Singer FR, Mells BG, Gruber HE, Windle JJ, Roodman GD. Ultrastructure of bone cells in Paget’s disease of bone. J Bone Miner Res. 2006;21(Supp 2):51-54.

34. Rebel A, Basle M, Pouplard A, Kouyoumdjian S, Filmon R, Lepatezour A. Viral antigens in osteoclasts from Paget's disease of bone. Lancet. 1980;2:344-346.

35. Mills BG, Singer FR, Weiner LP, Suffin SC, Stabile E, Holst P. Evidence for both respiratory syncytial virus and measles virus antigens in the osteoclasts of patients with Paget's disease of bone. Clin Orthop. 1984:303-311.

36. Reddy SV, Singer FR, Roodman GD. Bone marrow mononuclear cells from patients with Paget's disease contain measles virus nucleocapsid messenger ribonucleic acid that has mutations in a specific region of the sequence. J Clin Endocrinol Metab. 1995;80:2108-2111.

37. Helfrich MH, Hobson RP, Grabowski PS, Zurbriggen A, Cosby SL, Dickson GR, Fraser WD, Ooi CG, Selby PL, Crisp AJ, Wallace RG, Kahn S, Ralston SH. A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res. 2000;15:2315-2329.

38. Freidrichs WE, Reddy S, V., Bruder JM, Cundy T, Cornish J, Singer FR, Roodman GD. Sequence Analysis of Measles Virus Nucleocapsid Transcripts in Patients with Paget's Disease. J Bone and Miner Res. 2002;17:145.

39. Nagant de Deuxchaisnes C, Krane S. Paget's disease of bone: Clinical and metabolic observations. Medicine. 1964;43:233-266.

40. Randall AG, Kent GN, Garcia-Webb P, Bhagat CI, Pearce DJ, Gutteridge DH, Prince RL, Stewart G, Stuckey B, Will RK, Retallack RW, Price RI, Ward L. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links. J Bone Miner Res. 1996;11:1176-1184.

41. Franck WA, Bress NM, Singer FR, Krane SM. Rheumatic manifestations of Paget's disease of bone. Am J Med. 1974;56:592-603.

42. Woodard HQ, Marcove RC. A comparison of the chemistry of blood from bone and peripheral veins. Clin Orthop. 1969;66:254-264.

43. Panigrahi K, Delmas PD, Singer F, Ryan W, Reiss O, Fisher R, Miller PD, Mizrahi I, Darte C, Kress BC, Christenson RH. Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem. 1994;40:822-828.

44. Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, Rutland MD, Cundy T. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget’s disease of bone. Bone. 2004;35:224-230.

45. Gutteridge DH, Gruber HE, Kermode DG, Worth GK. Thirty cases of concurrent Paget's disease and primary hyperparathyroidism: sex distribution, histomorphometry, and prediction of the skeletal response to parathyroidectomy. Calcif Tissue Int. 1999;65:427-435.

46. Kanis JA, Heynen G, Walton RJ. Plasma calcitonin in Paget's disease of bone. Clin Sci Mol Med. 1977;52:329-332.

47. Guillard-Cumming DF, Beard DJ, Douglas DL, Johnson SK, Lawson-Matthew PJ, Russel RG, Kanis JA. Abnormal vitamin D metabolism in Paget's disease of bone. Clin Endocrinol (Oxf). 1985;22:559-566.

48. Hadjipavlou A, Lander P, Srolovitz H, Enker IP. Malignant transformation in Paget disease of bone. Cancer. 1992;70:2802-2808.

49. Jaffe H. Metabolic, Degenerative, and Inflammatory Diseases of Bones and Joints. . Philadelphia: Lea and Febiger; 1972.

50. Deyrup AT, Montag AG, Inwards CY, Xu Z, Swee RG, Krishnan Unni K. Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases. Arch Pathol Lab Med. 2007:131(6):942-6.

51. Seret P, Basle MF, Rebel A, Renier JC, Saint-Andre JP, Bertrans G, Audran M. Sarcomatous degeneration in Paget's bone disease. J Cancer Res Clin Oncol. 1987;113:392-399.

52. Huvos AG. Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. Cancer. 1986;57:1442-1449.

53. Singer FR, Mills BG. Giant cell tumor arising in Paget's disease of bone. Recurrences after 36 years. Clin Orthop. 1993:293-301.

54. Upchurch KS, Simon LS, Schiller AL, Rosenthal DI, Campion EW, Krane SM. Giant cell reparative granuloma of Paget's disease of bone: a unique clinical entity. Ann Intern Med. 1983;98:35-40.

55. Ziambaras K, Totty WA, Teitelbaum SL, Dierkes M, Whyte MP. Extraskeletal osteoclastomas responsive to dexamethasone treatment in Paget bone disease. J Clin Endocrinol Metab. 1997;82:3826-3834.

56. Reifenstein, EC Jr, Albright F. Paget's disease: Its pathologic physiology and the importance of this in the complications arising from fracture and immobilization. N Engl J Med. 1944;231:343-355.

57. Rosenkrantz J, Gluckman E. Coexistence of Paget's disease of bone and multiple myeloma. AJR. 1957;78:30-38.

58. Altman RD. Musculoskeletal manifestations of Paget's disease of bone. Arthritis Rheum. 1980;23:1121-1127.

59. Fennelly JJ, Hogan A. Pseudouridine excretion--a reflection of high RNA turnover in Paget's disease. Ir J Med Sci. 1972;141:103-107.

60. Edholm O, Howarth S. Studies on the peripheral circulation in osteitis deformans. Clin Sci. 1953;12:277-285.

61. Heistad DD, Abboud FM, Schmid PG, Mark AL, Wilson WR. Regulation of blood flow in Paget's disease of bone. J Clin Invest. 1975;55:69-74.

62. Morales-Piga AA, Moya JL, Bachiller FJ, Munoz-Malo MT, Benavides J, Abraira V. Assessment of cardiac function by echocardiography in Paget's disease of bone. Clin Exp Rheumatol. 2000;18:31-37.

63. Arnalich F, Plaza I, Sobrino JA, Oliver J, Barbado J, Pena JM, Vasquez JJ. Cardiac size and function in Paget's disease of bone. Int J Cardiol. 1984;5:491-505.

64. Strickberger SA, Schulman SP, Hutchins GM. Association of Paget's disease of bone with calcific aortic valve disease. Am J Med. 1987;82:953-956.

65. Hultgren HN. Osteitis deformans (Paget's disease) and calcific disease of the heart valves. Am J Cardiol. 1998;81:1461-1464.

66. Harrison C, Lennox B. Heart block in osteitis deformans. Br Heart J. 1948;10:167-176.

67. Laroche M, Delmotte A. Increased arterial calcification in Paget’s disease of bone. Calcif Tissue Int. 2005;77(3)129-33.

68. Blotman F, Blard JM, Labauge R, Simon L. [Ultrasonic study of the brain circulation in patients with Paget's disease. Preliminary results]. Rev Rhum Mal Osteoartic. 1975;42:647-651.

69. Douglas DL, Duckworth T, Kanis JA, Jefferson AA, Martin TJ, Russell RG. Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis? J Bone Joint Surg Br. 1981;4:495-503.

70. Woodhouse NJ, Crosbie WA, Mohamedally SM. Cardiac output in Paget's disease: response to long-term salmon calcitonin therapy. Br Med J. 1975;4:686.

71. Chen JR, Rhee RS, Wallach S, Avramides A, Flores A. Neurologic disturbances in Paget disease of bone: response to calcitonin. Neurology. 1979;29:448-457.

72. el Sammaa M, Linthicum FH, Jr., House HP, House JW. Calcitonin as treatment for hearing loss in Paget's disease. Am J Otol. 1986;7:241-243.

73. Meyers MH, Singer FR. Osteotomy for tibia vara in Paget's disease under cover of calcitonin. J Bone Joint Surg Am. 1978;60:810-814.

74. Nagant de Deuxchaisnes C, Maldague B, Malghem J, Devogelaer JP, Huax JP, Rombouts-Lindemans C. The action of the main therapeutic regimes on Paget's disease of bone with a note on the effect of vitamin D deficiency. Arthritis Rhem. 1980;23:1215-1234.

75. Waxman AD, Ducker S, McKee D, Siemsen JK, Singer FR. Evaluation of 99mTc bisphosphonate kinetics and bone scans in patients with Paget’s disease before and after calcitonin treatment. Radiology. 1977;125:761-764.

76. Fornasier VL, Stapleton K, Williams CC. Histologic changes in Paget's disease treated with calcitonin. Hum Pathol. 1978;9:455-461.

77. Singer FR, Fredericks RS, Minkin C. Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance. Arthritis Rheum. 1980;23:1148-1154.

78. Nagant de Deuxchaisnes C, Devogelaer JP, Huaux JP, Dufour JP, Esselinckx W, Engelbeen JP, Stasse P, Hermans P, de Buisseret JP. New modes of administration of salmon calcitonin in Paget's disease. Nasal spray and suppository. Clin Orthop. 1987:56-71.

79. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007;1117:209-57.

80. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000; 60: 6001-6007.

81. Cundy T, Wattie D, King AR. High-dose pamidronate in the management of resistant Paget's disease. Calcif Tissue Int. 1996;58:6-8.

82. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med. 2005;353(9):898-908.

83. Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Lowik CW, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res. 1995;10:956-962.

84. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol. 1994;118:220-224.

85. Krane SM. Etidronate disodium in the treatment of Paget's disease of bone. Ann Intern Med. 1982;96:619-625.

86. Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelear JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EP, Reid IR. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res. 2007;22(1):142-8.

87. Eekhoff ME, Zwinderman AH, Haverkort DM, Cremers SC, Hamdy NA, Papapoulos SE. Determinants of induction and duration of remission of Paget’s disease of bone after bisphosphonate (olpadronate) therapy. Bone. 2003;33: 831-838.

88. Meunier P, Ravault A. Treatment of Paget's disease with etidronate disodium. In Singer FR, Wallach S (eds): Paget's Disease of Bone, Clinical Assessment, Present and Future Therapy. New York: Elsevier; 1991:86-99.

89. Gutteridge DH, Ward LC, Stewart GO, et al. Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. J Bone Miner Res. 1999;14 Suppl 2:79-84.

90. Rendina D, Mossetti G, Viceconti R, Sorrentino M, Nunziata V. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget’s disease of bone and acquired resistance to bisphosphonates. Calcif Tissue Int. 2004;75: 189-196.

91. Murad OM, Arora S, Farag AF, Guber HA. Bisphosphates and osteonecrosis of the jaw: a retrospective study. Endocr Pract. 2007;13(3):232-8.

92. Ryan WG. Two decades of experience in the treatment of Paget's disease of bone with plicamycin (mithramycin). In Singer, FR, Wallach S (eds): Paget's Disease of Bone, Clinical Assessment, Present and Future Therapy. New York: Elsevier; 1991:176-190.

93. Warrell RP, Jr., Bosco B, Weinerman S, Levine B, Lane J, Bockman RS. Gallium nitrate for advanced Paget disease of bone: effectiveness and dose-response analysis. Ann Intern Med. 1990;113:847-851.

94. Ludkowski P, Wilson-MacDonald J. Total arthroplasty in Paget's disease of the hip. A clinical review and review of the literature. Clin Orthop. 1990:160-167.

95. Lusty PJ, Walter WL, Walter WK, Zicat B. Cementless hip arthroplasty in Paget’s disease at medium-term follow-up (average of 6.7 years). J Arthroplasty. 2007;22(5):692-6.

96. Lee GC, Sanchesz-Sotelo J, Berry DJ. Total knee arthroplasty in patients with Paget’s disease of bone at the knee. J Arthroplasty. 2005;20(6):689-93.

97. Hartman JT, Dohn DF. Paget's disease of the spine with cord or nerve-root compression. J Bone Joint Surg Am. 1966;48:1079-1084.

98. Bacciu A, Pasanisi E, Vincenti V, Ingegnoli F, Guida M, Panu F, Bacciu S. Paget’s disease and cochlear implantation. 2004; 118:810-813.

99. Kurihara N, Zhou H, Reddy SV, Garcia Palacios V, Subler MA, Dempster DW, Windle JJ, Roodman GD. Expression of measles virus nucleocapsid protein in osteoclasts induces Paget’s disease-like bone lesions in mice. J Bone Miner Res. 2006;21(3):446-55.

100. Leach RJ, Singer FR, Roodman GD. The genetics of Paget's disease of the bone. J Clin Endocrinol Metab. 2001;86:24-28.

101. Cody JD, Singer FR, Roodman GD, Otterund B, Lewis TB, Leppert M, Leach RJ. Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet. 1997;61:1117-1122.

102. Haslam SI, Van Hul W, Morales-Piga A, Balemans W, San-Millan JL, Nakatsuka K, Willems P, Haites NE, Ralston SH. Paget's disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res. 1998;13:911-917.

103. Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000;24:45-48.

104. Wallace RG, Barr RJ, Osterberg PH, Mollan RA. Familial expansile osteolysis. Clin Orthop. 1989:265-277.

105. Good DA, Busfield F, Fletcher BH, Duffy DL, Kesting JB, Andersen J, Shaw JT. Linkage of Paget Disease of Bone to a Novel Region on Human Chromosome 18q23. Am J Hum Genet. 2001;70:2.

106. Nellissery MJ, Padalecki SS, Brkanac Z, Singer FR, Roodman GD, Unni KK, Leach RJ, Hansen MF. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am J Hum Genet. 1998;63:817-824.

107. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002; 70: 1582-1588.

108. Rea SL, Walsh JP, Ward L, Yip K, Kent GN, Steer JH, Xu J, Ratajczak T. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget’s disease of bone with a severe phenotype. J Bone Miner Res. 2006;21(7):1136-45.

109. Collet C, Michou L, Audran M, Chasseigneaux S, Hilliquin P, Bardin T, Lemaire I, Cornelis F, Launay JM, Orcel P, Laplanche JL. Paget’s disease of bone in the French population: novel SQSTM1 mutations, functional analysis, and genotype-phenotype correlations. J Bone Miner Res. 2007;22(2):310-7.

110. Watts GDJ, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE. Nature Genetics. 2004; 36: 377-381.

111. Guinto JB, Ritson GP, Taylor JP, Forman MS. Valosin-containing protein and the pathogenesis of frontotemporal dementia associated with inclusion body myopathy. Acta Neuropathol. 2007;114:55-61.

112. Lucas GJ, Mehta SG, Hocking LJ, Stewart TL, Cundy T, Nicholson GC, Walsh JP, Fraser WD, Watts GD, Ralston SH, Kimonis VE. Evaluation of the role of Valosin-containing protein in the pathogenesis of familial and sporadic Paget’s disease of bone. Bone. 2006;38(2):280-5.

113. Laurin N, Brown JP, Lemainque A, Duchesne A, Huot D, Lacourciere Y, Drapeau G, Verrault J, Raymond V, Morissette J. Paget disease of bone: mapping of two loci at 5Q35-qter and 5q31. Am J Hum Genet. 2001, 69: 528-543.

114. Hocking LJ, Herbert CA, Nicholls RK, Williams F, Bennett ST, Cundy T, Nicholson GC, Wuyts W, Van Hul W, Ralston SH. Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. Am J Hum Genet. 2001;69:1055-1061.

115. Lucas GJ, Riches PL, Hocking LJ, Cundy T, Nicholson GC, Walsh JP, Ralston SH. Identification of a Major Locus for Paget’s Disease on Chromosome 10p13 in Families of British Descent. J Bone Miser Res. 2008;23(1):58-63.

116. Wuyts W, Van Wesenbeeck L, Morales-Piga A, Ralston S, Hocking L, Vanhoenacker R, Westhovens R, Verbruggen L, Anderson D, Hughes A, Van Hul W. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone. 2001;28:104-107.

117. Daroszewska A, Hocking LJ, McGuigan FE, Langdahl B, Stone MD, Cundy T, Nicholson GC, Fraser WD, Ralston SH. Susceptibility to Paget’s disease of bone is influenced by a common polymorphic variant of osteoprotegerin. J Bone Miner Res. 2004; 19:1506-1511.

118. Donath J, Speer G, Poor G, Gergely P Jr, Tabak A, Lakatos P. Vitamin D receptor, oestrogen receptor-alpha and calcium-sensing receptor genotypes, bone mineral density and biochemical markers in Paget’s disease of bone. Rheumatology (Oxford). 2004; 43: 692-695.

119. Bolland MJ, Tong PC, Naot D, Callon KE, Wattie DJ, Gamble GD, Cundy T. Delayed development of Paget’s disease in offspring inheriting SQSTM1 mutations. J Bone Miser Res. 2007;22(3):411-5.

120. Kurihara N, Hiruma Y, Zhou H, Subler MA, Dempster DW, Singer FR, Reddy SV, Gruber HE, Windle JJ, Roodman GD. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest. 2007;117(1):133-42.